Suchergebnisse - "Paoletti, Xavier"

PubPharm (205)

101

Design and statistical principles of the SHIVA trial

enthalten in: Chinese clinical oncology | 2015

von Paoletti, X. | Asselain, B. | Kamal, M. | +4

102

Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales : utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma

enthalten in: The oncologist | 2015

von Diouf, M. | Bonnetain, F. | Barbare, J. | +4

103

The role of the expansion cohort in phase I trials in oncology : guidelines of the phase I HUB

enthalten in: Bulletin du cancer | 2015

von Ezzalfani, M. | Dugué, A. | Mollevi, C. | +15

104

Long-term follow-up of TaG1 non-muscle-invasive bladder cancer

enthalten in: Urologic oncology | 2015

von Olivier Bosset, P. | Neuzillet, Y. | Paoletti, X. | +3

CommentIn: J Urol. 2017 Jan;197(1):52-54. - PMID 27979569

105

Long-term follow-up of TaG1 non-muscle-invasive bladder cancer

enthalten in: Urologic oncology | 2015

von Olivier Bosset, P. | Neuzillet, Y. | Paoletti, X. | +3

106

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

enthalten in: The lancet / Oncology | 2015

von Le Tourneau, C. | Delord, J. | Gonçalves, A. | +20

107

Precision medicine: lessons learned from the SHIVA trial - Authors' reply

enthalten in: The lancet / Oncology | 2015

von Le Tourneau, C. | Belin, L. | Paoletti, X. | +2

108

Dose finding with longitudinal data: simpler models, richer outcomes

enthalten in: Statistics in medicine | 2015

von Paoletti, X. | Doussau, A. | Ezzalfani, M. | +2

109

Optimal Cut Points for Quality of Life Questionnaire‐Core 30 (QLQ‐C30) Scales : Utility for Clinical Trials and Updates of Prognostic Systems in Advanced Hepatocellular Carcinoma

enthalten in: The oncologist | 2015

von Diouf, M. | Bonnetain, F. | Barbare, J. | +4

110

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2014

von Postel-Vinay, S. | Collette, L. | Paoletti, X. | +14

CommentIn: Eur J Cancer. 2014 Aug;50(12):2037-9. - PMID 24908539